ID   JY
AC   CVCL_0108
SY   JY-S
DR   BTO; BTO:0003044
DR   CLO; CLO_0037202
DR   ChEMBL-Cells; CHEMBL3308061
DR   ChEMBL-Targets; CHEMBL613833
DR   dbMHC; 48917
DR   ECACC; 94022533
DR   IHW; IHW09287
DR   IPD-IMGT/HLA; 10882
DR   PRIDE; PXD000394
DR   PRIDE; PXD001872
DR   PRIDE; PXD006939
DR   PRIDE; PXD028633
DR   PRIDE; PXD028874
DR   PubChem_Cell_line; CVCL_0108
DR   Wikidata; Q6109290
RX   PubMed=6294325;
RX   PubMed=6417007;
RX   PubMed=22238296;
RX   PubMed=23619976;
RX   PubMed=25576301;
RX   PubMed=25960936;
RX   PubMed=28360230;
RX   PubMed=29242379;
RX   PubMed=30844424;
RX   PubMed=34925382;
WW   https://en.wikipedia.org/wiki/JY_cell_line
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/j/cell-lines-detail-50.html
CC   Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC   Population: Caucasian; Amish.
CC   Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=22238296).
CC   HLA typing: A*02:01,02:01; B*07:02,07:02; C*07:02,07:02; DQA1*03:02,01:03; DQB1*06:11,03:02; DRB1*04:04,13:01 (PubMed=25960936).
CC   HLA typing: A*02:01:01:01; B*07:02:01:01; C*07:02:01:01,07:02:01:03; DPA1*01:03; DPB1*02:01:02:01,04:01; DQA1*01:03,03:01:01; DQB1*03:02;06:03; DRA*01:01:01:01,01:02:01; DRB1*04:04,13:01 (IPD-IMGT/HLA=10882).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: MHC region genome.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=6294325; DOI=10.1128/JVI.44.3.1088-1091.1982;
RA   Skare J., Edson C., Farley J., Strominger J.L.;
RT   "The B95-8 isolate of Epstein-Barr virus arose from an isolate with a
RT   standard genome.";
RL   J. Virol. 44:1088-1091(1982).
//
RX   PubMed=6417007; DOI=10.1007/BF00364387;
RA   Bono M.R., Strominger J.L.;
RT   "NH2-terminal sequence of the alpha and beta chains of human DC-1
RT   antigen isolated from the JY cell line. Homology with murine I-A
RT   molecules.";
RL   Immunogenetics 18:453-459(1983).
//
RX   PubMed=22238296; DOI=10.1128/JVI.06717-11;
RA   Lin Z., Puetter A., Coco J., Xu G.-R., Strong M.J., Wang X., Fewell C.,
RA   Baddoo M., Taylor C., Flemington E.K.;
RT   "Detection of murine leukemia virus in the Epstein-Barr virus-positive
RT   human B-cell line JY, using a computational RNA-Seq-based exogenous
RT   agent detection pipeline, PARSES.";
RL   J. Virol. 86:2970-2977(2012).
//
RX   PubMed=23619976; DOI=10.1007/s00262-013-1412-z;
RA   Neumann F., Kaddu-Mulindwa D., Widmann T., Preuss K.-D., Held G.,
RA   Zwick C., Roemer K., Pfreundschuh M., Kubuschok B.;
RT   "EBV-transformed lymphoblastoid cell lines as vaccines against cancer
RT   testis antigen-positive tumors.";
RL   Cancer Immunol. Immunother. 62:1211-1222(2013).
//
RX   PubMed=25576301; DOI=10.1074/mcp.M114.042812;
RA   Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M.;
RT   "Mass spectrometry of human leukocyte antigen class I peptidomes
RT   reveals strong effects of protein abundance and turnover on antigen
RT   presentation.";
RL   Mol. Cell. Proteomics 14:658-673(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=28360230; DOI=10.1101/gr.213538.116;
RA   Norman P.J., Norberg S.J., Guethlein L.A., Nemat-Gorgani N., Royce T.,
RA   Wroblewski E.E., Dunn T., Mann T., Alicata C., Hollenbach J.A.,
RA   Chang W.-H., Shults Won M., Gunderson K.L., Abi-Rached L., Ronaghi M.,
RA   Parham P.;
RT   "Sequences of 95 human MHC haplotypes reveal extreme coding variation
RT   in genes other than highly polymorphic HLA class I and II.";
RL   Genome Res. 27:813-823(2017).
//
RX   PubMed=29242379; DOI=10.1074/mcp.TIR117.000383;
RA   Chong C., Marino F., Pak H., Racle J., Daniel R.T., Muller M.,
RA   Gfeller D., Coukos G., Bassani-Sternberg M.;
RT   "High-throughput and sensitive immunopeptidomics platform reveals
RT   profound interferon gamma-mediated remodeling of the human leukocyte
RT   antigen (HLA) ligandome.";
RL   Mol. Cell. Proteomics 17:533-548(2018).
//
RX   PubMed=30844424; DOI=10.1016/j.humimm.2019.03.001;
RA   Creary L.E., Guerra S.G., Chong W., Brown C.J., Turner T.R.,
RA   Robinson J., Bultitude W.P., Mayor N.P., Marsh S.G.E., Saito K.,
RA   Lam K., Duke J.L., Mosbruger T.L., Ferriola D., Monos D.S., Willis A.,
RA   Askar M., Fischer G.F., Saw C.L., Ragoussis J., Petrek M.,
RA   Serra-Pages C., Juan Otero M., Stavropoulos-Giokas C., Dinou A., Ameen R.,
RA   Al Shemmari S., Spierings E., Gendzekhadze K., Morris G.P., Zhang Q.-H.,
RA   Kashi Z., Hsu S., Gangavarapu S., Mallempati K.C., Yamamoto F.,
RA   Osoegawa K., Vayntrub T., Chang C.-J., Hansen J.A.,
RA   Fernandez-Vina M.A.;
RT   "Next-generation HLA typing of 382 International Histocompatibility
RT   Working Group reference B-lymphoblastoid cell lines: report from the
RT   17th International HLA and Immunogenetics Workshop.";
RL   Hum. Immunol. 80:449-460(2019).
//
RX   PubMed=34925382; DOI=10.3389/fimmu.2021.796584;
RA   Mukherjee S., Sanchez-Bernabeu A., Demmers L.C., Wu W., Heck A.J.R.;
RT   "The HLA ligandome comprises a limited repertoire of O-GlcNAcylated
RT   antigens preferentially associated with HLA-B*07:02.";
RL   Front. Immunol. 12:796584.1-796584.10(2021).
//